Anlotinib and benmelstobart before kidney-sparing surgery for localized kidney cancer
Tests anlotinib with benmelstobart before partial nephrectomy in adults with localized renal cell carcinoma.
Plain-language title generated from the registry record
Registry title: Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy
Key facts
- Where
- Beijing, Changchun, Changsha, Hangzhou, Kunming, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, and Zhengzhou, ChinaSee the 14 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07627464, who can take part
Where in China
- Peking University Third HospitalBeijing, ChinaNo longer taking part
- Jilin Provincial Cancer HospitalChangchun, ChinaNo longer taking part
- Hunan Provincial Cancer HospitalChangsha, ChinaNo longer taking part
- The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaNo longer taking part
- Yunnan Provincial Cancer HospitalKunming, ChinaNo longer taking part
- Nanjing Drum Tower hospitalNanjing, ChinaNo longer taking part
- The First Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaNo longer taking part
- The Affiliated Hospital of Qingdao UniversityQingdao, ChinaNo longer taking part
- Huadong Hospital Affiliated to Fudan UniversityShanghai, ChinaNo longer taking part
- Liaoning Provincial Cancer HospitalShenyang, ChinaNo longer taking part
- Shanxi Province Cancer HospitalTaiyuan, ChinaNo longer taking part
- Tianjin Medical University Cancer Institute and HospitalTianjin, ChinaNo longer taking part
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaNo longer taking part
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tianjin Medical University Cancer Institute and Hospital
- Trial code
- NCT07627464
- Record updated
- 4 June 2026
- Original description
Evaluation of long-term renal function improvement, surgical safety, as well as efficacy and safety of preoperative anlotinib hydrochloride capsules combined with benmelstobart injection versus surgery in patients with localized renal cell carcinoma undergoing partial nephrectomyRead full original descriptionShow less
A Multicenter, Randomized Controlled Phase II Study of Neoadjuvant Anlotinib Hydrochloride Capsules Combined With Benmelstobart Injection Versus Surgery Alone for Localized Renal Cell Carcinoma Planned for Partial Nephrectomy
Evaluation of long-term renal function improvement, surgical safety, as well as efficacy and safety of preoperative anlotinib hydrochloride capsules combined with benmelstobart injection versus surgery in patients with localized renal cell carcinoma undergoing partial nephrectomy
Inclusion: Aged between 18 and 75 years, inclusive; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Subjects with newly diagnosed cT1bN0M0 renal cell carcinoma (RCC) scheduled to undergo partial nephrectomy; Have at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; No prior systemic therapy for renal cell carcinoma, including but not limited to targeted therapy, immunotherapy, investigational therapy, or hormone therapy.
Exclusion: Subjects with a prior history of renal transplantation; Subjects with hereditary or familial renal tumors (e.g., von Hippel-Lindau [VHL] disease); Subjects with a solitary kidney tumor; Subjects with bilateral renal tumors or unilateral multiple renal tumors (n ≥ 2).